Illumina Inc. (ILMN): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Illumina ( ILMN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole was unchanged today. By the end of trading, Illumina rose 86 cents (1.6%) to $53.22 on light volume. Throughout the day, 1.1 million shares of Illumina exchanged hands as compared to its average daily volume of 1.8 million shares. The stock ranged in a price between $52.30-$53.43 after having opened the day at $52.59 as compared to the previous trading day's close of $52.36. Other companies within the Health Care sector that increased today were: YM Biosciences ( YMI), up 76.7%, Idera Pharmaceuticals ( IDRA), up 35.3%, AspenBio Pharma ( APPY), up 30.1%, and ARCA biopharma ( ABIO), up 24.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $6.43 billion and is part of the drugs industry. The company has a P/E ratio of 74.5, above the S&P 500 P/E ratio of 17.7. Shares are up 71.1% year to date as of the close of trading on Tuesday. Currently there are seven analysts that rate Illumina a buy, one analyst rates it a sell, and seven rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Acura Pharmaceuticals ( ACUR), down 15.2%, USMD Holdings ( USMD), down 12.7%, IsoRay ( ISR), down 11.5%, and MEI Pharma ( MEIP), down 10.2%, were all laggards within the health care sector with Celgene Corporation ( CELG) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

Cramer: Lessons From the Market and ICR

Cramer: Lessons From the Market and ICR

Six Off the Beaten Path Healthcare Stock Gems

Six Off the Beaten Path Healthcare Stock Gems

16 Amazing Stocks to Trade in This Unstoppable Bull Market

16 Amazing Stocks to Trade in This Unstoppable Bull Market

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017